EP4646247A1 - Dispositif d'administration de médicament - Google Patents

Dispositif d'administration de médicament

Info

Publication number
EP4646247A1
EP4646247A1 EP23837222.1A EP23837222A EP4646247A1 EP 4646247 A1 EP4646247 A1 EP 4646247A1 EP 23837222 A EP23837222 A EP 23837222A EP 4646247 A1 EP4646247 A1 EP 4646247A1
Authority
EP
European Patent Office
Prior art keywords
medicament delivery
plunger rod
delivery device
rotatable
activation ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP23837222.1A
Other languages
German (de)
English (en)
Inventor
Anders BOSTRÖM
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SHL Medical AG
Original Assignee
SHL Medical AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SHL Medical AG filed Critical SHL Medical AG
Publication of EP4646247A1 publication Critical patent/EP4646247A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
    • A61M5/2033—Spring-loaded one-shot injectors with or without automatic needle insertion
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/24—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
    • A61M5/31501—Means for blocking or restricting the movement of the rod or piston
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
    • A61M5/31565—Administration mechanisms, i.e. constructional features, modes of administering a dose
    • A61M5/31576—Constructional features or modes of drive mechanisms for piston rods
    • A61M5/31578—Constructional features or modes of drive mechanisms for piston rods based on axial translation, i.e. components directly operatively associated and axially moved with plunger rod
    • A61M5/3158—Constructional features or modes of drive mechanisms for piston rods based on axial translation, i.e. components directly operatively associated and axially moved with plunger rod performed by axially moving actuator operated by user, e.g. an injection button
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
    • A61M5/31565—Administration mechanisms, i.e. constructional features, modes of administering a dose
    • A61M5/31576—Constructional features or modes of drive mechanisms for piston rods
    • A61M5/31583—Constructional features or modes of drive mechanisms for piston rods based on rotational translation, i.e. movement of piston rod is caused by relative rotation between the user activated actuator and the piston rod
    • A61M5/31586—Constructional features or modes of drive mechanisms for piston rods based on rotational translation, i.e. movement of piston rod is caused by relative rotation between the user activated actuator and the piston rod performed by rotationally moving or pivoted actuator, e.g. an injection lever or handle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
    • A61M2005/2006—Having specific accessories
    • A61M2005/2013—Having specific accessories triggering of discharging means by contact of injector with patient body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
    • A61M5/31501—Means for blocking or restricting the movement of the rod or piston
    • A61M2005/31508—Means for blocking or restricting the movement of the rod or piston provided on the piston-rod

Definitions

  • the present disclosure relates to a medicament delivery device and in particular to a medicament delivery device comprising a rotatable plunger rod.
  • a medicament delivery device in particular an autoinjector, according to the prior art comprises a housing comprising a front housing and a rear housing.
  • the housing is adapted to hold a medicament container, such as a syringe.
  • the syringe may be a pre-filled syringe and have a needle as a medicament delivery member arranged at a proximal end.
  • a protective needle sheath may be removably coupled to the needle.
  • the protective needle sheath may be made of a flexible shell (for instance composed of rubber) and/or a rigid shell (for instance composed of plastic).
  • a stopper also called plunger, may be arranged for sealing the syringe distally and for expelling a medicament contained in the syringe through the needle.
  • the medicament container may be a cartridge which includes the medicament and engages a removable needle (e.g., by threads, snaps, friction, etc.).
  • a cap may be removably disposed at a proximal end of the housing.
  • the cap may include an element (e.g., a barb, a hook, a narrowed section, etc.) arranged to engage the protective needle sheath, the housing and/or a medicament delivery member cover, also referred to as needle cover, telescoped within the housing.
  • the cap may comprise grip features for facilitating removal of the cap (e.g., by twisting and/or pulling the cap relative to the housing).
  • a medicament delivery member cover biasing member may be arranged to bias the medicament delivery member cover in a proximal direction relative to the housing, before injection, for safety reasons. The medicament delivery member cover biasing member needs to be compressed at the beginning of injection in order to retract the medicament delivery member cover inside the housing and uncover the medicament delivery member, thereby activating the device.
  • a pre-loaded drive biasing member for instance a pre-compressed drive spring, may be arranged within the housing.
  • a plunger rod may be used to forward force from the drive biasing member to the stopper.
  • the plunger rod is hollow and the drive biasing member is arranged within the plunger.
  • the plunger rod is solid and the drive biasing member engages a distal end of the plunger rod.
  • the pre-loaded drive biasing member is released, the drive biasing member biases the plunger rod in the proximal direction relative to the housing, releasing the plunger rod.
  • the plunger rod may itself comprise means for sealing the medicament container such that no stopper needs to be provided.
  • a plunger rod release mechanism may be arranged for preventing release of the plunger rod prior to retraction of the medicament delivery member cover relative to the housing and for releasing the plunger rod only once the medicament delivery member cover is sufficiently retracted.
  • a medicament delivery member cover lock mechanism may be arranged to prevent retraction of the medicament delivery member cover relative to the housing when the cap is in place, thereby avoiding unintentional activation of the autoinjector (e.g., if dropped, during shipping or packaging, etc.).
  • Such mechanisms are known in the art and will not be described in detail. However, there is a need to further simplify the structure of medicament delivery devices while effectively preventing inadvertent activation of the device.
  • the invention relates to a medicament delivery device, comprising: a rear housing provided at a distal end of the medicament delivery device, wherein the distal end is pointing away from a medicament delivery site during use of the medicament delivery device, a medicament delivery member cover, a rotatable activation ring, and a rotatable plunger rod, wherein the medicament delivery member cover comprises at least one sloped surface configured to interact with at least one corresponding sloped protrusion provided on the rotatable activation ring, wherein the activation ring comprises at least one recess configured to interact with at least one corresponding boss provided on the rotatable plunger rod, wherein the boss abuts a stop rib provided at the rear housing, wherein the stop rib extends in a circumferential direction with respect to a longitudinal axis of the medicament delivery device and is configured to block, in an assembled state and activation state of the medicament delivery device, a movement of the plunger rod in a proximal direction towards the medicament delivery site, wherein the at least
  • the stop rib comprises a stop notch provided at the circumferential end in the rotating direction of the plunger rod, and the stop notch extends in a distal direction.
  • the medicament delivery device further comprises a drive biasing member configured to provide a force to the plunger rod able to bias the plunger rod in the proximal direction.
  • the medicament delivery member comprises two arms extending in a distal direction, and the sloped surfaces are located at respective distal ends of the arms.
  • the plunger rod is provided inside the activation ring in a radial direction with respect to the longitudinal axis and the activation ring is provided inside the rear housing and the medicament delivery member cover, respectively, in the radial direction.
  • the rear housing comprises two housing arms extending in a proximal direction, and the stop rib is provided on each of the two housing arms, and preferably, the stop rib protrudes radially inwards.
  • the boss protrudes radially outwards.
  • the sloped protrusion protrudes radially outwards.
  • the housing arms and the medicament delivery member cover arms are offset by 90 degrees, in alternating order.
  • the invention is specified by the independent claim. Preferred embodiments are defined in the dependent claims. In the following description, although numerous features may be designated as optional, it is nevertheless acknowledged that all features comprised in the independent claims are not to be read as optional.
  • distal direction refers to the direction pointing away from the dose delivery site during use of the medicament delivery device.
  • distal part/end refers to the part/end of the delivery device, or the parts/ends of the members thereof, which during use of the medicament delivery device is/are located furthest away from the dose delivery site.
  • proximal direction refers to the direction pointing towards the dose delivery site during use of the medicament delivery device.
  • proximal part/end this refers to the part/end of the delivery device, or the parts/ends of the members thereof, which during use of the medicament delivery device is/are located closest to the dose delivery site.
  • transverse refers to a direction generally perpendicular to the longitudinal direction.
  • circumference refers to a circumference or a circumferential direction relative to an axis, typically a longitudinal axis extending in the direction of the longest extension of the device and/or component.
  • radial or “radially” refer to a direction extending radially relative to the axis
  • rotation refers to rotation relative to the axis.
  • Figure 2 shows an exploded view of a medicament delivery device according to a non-limiting embodiment of the invention.
  • Figure 4A shows a partial view of Figure 1 and Figure 4B shows a partial view of Figure s.
  • Figure 5 shows a rear housing of a medicament delivery device according to a non-limiting embodiment of the invention.
  • Figure 6A shows a partial view of Figure 1
  • Figure 6B shows a partial view of Figure s.
  • the (rotating) plunger rod activation mechanism as described herein can be applied to a number of medicament delivery devices. Hence, only the elements which are important for releasing a rotating plunger rod are further described.
  • Fig. 1 shows a partial view of an exemplary medicament delivery device in an assembled state.
  • the assembled state herein refers to a state in which the device is delivered to the patient, i.e., before activation and medicament delivery.
  • the medicament delivery device extends generally along a longitudinal axis and comprises a plunger rod 4 extending along the longitudinal axis too.
  • the plunger rod 4 In an assembled state, the plunger rod 4 is in a locked position. In an activation state, the plunger rod is rotated, but still locked in the axial direction. In an activated state, the plunger rod is free to move in the proximal direction for medicament delivery.
  • the plunger rod 4 may thus be displaceable along the longitudinal axis.
  • Fig. 2 shows an exploded view of Fig. 1.
  • the medicament delivery device comprises a medicament delivery member cover 1, the plunger rod 4, and an activation ring 3 radially positioned between the medicament delivery member cover 1 and the plunger rod 4.
  • the plunger rod 4 and the activation ring 3 are both rotationally movable around the longitudinal axis.
  • the medicament delivery device has a housing preferably comprising a front (proximal) housing (not shown) and a rear (distal) housing 2.
  • the rear housing 2 may also be referred to as rear cap.
  • the front and rear housing may also be integrally provided according to a non-limiting embodiment.
  • the medicament delivery member cover 1 may be biased in a proximal direction by a spring or another energy accumulating member (not shown), to protect a medicament delivery member before activation.
  • a drive biasing member (not shown), for instance a coil spring, may be provided to push the plunger rod 4 in a proximal direction after activation, i.e., release of the plunger rod 4.
  • the plunger rod 4 comprises a boss 41.
  • the boss 41 may be provided at a distal end of the plunger rod 4.
  • the boss 41 is at the very distal end of the plunger rod 4, i.e., directly adjacent to a distally facing surface of the plunger rod 4.
  • the boss 41 maybe located at some distance from the distally facing surface, i.e., with an offset towards the proximal end of the plunger rod 4.
  • the activation ring 3 comprises a recess 32 corresponding to and configured to interact with the boss 41.
  • the recess 32 may be a groove or, as shown in the figures, a cut-out.
  • the length in axial direction of the recess 32 is adapted to accommodate the boss 41 to such extent that the plunger rod 4 is prevented from rotating by the lateral edges of the recess 32.
  • the length of the groove or recess hat to be correspondingly larger or the axial overlap of the activation ring 3 over the distal end of the plunger rod 4 has to be larger to compensate for the offset.
  • the activation ring 3 further comprises a sloped protrusion 31.
  • the protrusion 31 protrudes radially from the outer circumferential surface of the activation ring 31.
  • the sloped protrusion 31 is depicted as an essentially right-angled triangle (in cross-section when viewed in radial direction). One edge of the right angle extends parallel to the longitudinal axis, the other edge of the right angle extends parallel to a distal surface of the rear housing, and the slope is the edge opposite the right angle.
  • the edge opposite the right-angle could be curved, or the sloped protrusion may have another shape such as a round boss or a polygon which may alternatively be used to provide the intended functionality.
  • the activation ring 3 may be axially fixed relative to the housing.
  • the activation ring 3 may abut the distal end of the device, i.e., the rear housing 2, and the sloped surface 12 and may therefore be axially fixed between the rear housing 2 and the medicament delivery member cover 1.
  • the inner surface of the rear housing 2 comprises a stop rib 21 configured to block a movement of the plunger rod 4 in the proximal direction.
  • the plunger rod 4 is thus in a locked state in an axial direction but free to rotate.
  • the rear housing 2 may comprise two arms 23 extending in a proximal direction.
  • the rear housing arms 23 and the arms 11 of the medicament delivery member cover may be offset by 90 degrees as shown in the figures.
  • the stop rib 21 may be provided on a radially inner side of the housing arms 23 with respect to the longitudinal axis of the device.
  • the stop rib 21 may form a circular segment in a circumferential direction with respect to the longitudinal axis. In other words, the stop rib 21 may have an arc shape.
  • a stop notch 22 may be provided at a circumferential end of the stop rib 21 in a rotation direction of the activation ring 3 and the plunger rod 4. The stop notch 22 will be further described later.
  • the plunger rod 4 may be a substantially cylindrical element extending along the longitudinal axis of the device.
  • the plunger rod 4 may be provided inside the activation ring 3 in a radial direction with respect to the longitudinal axis and the activation ring 3 may be provided inside the rear housing 2 and the medicament delivery member cover 1, respectively, in the radial direction.
  • the activation ring 3 may substantially be a hollow cylinder. In other words, the activation ring 3 may partially receive the distal end of the plunger rod 4.
  • Fig. 3 shows the device of Figs. 1 and 2 in an activation state, meaning the medicament delivery member cover 1 has been pushed in a distal direction, e.g. by pushing the medicament delivery device on an injection/medicament delivery site, thereby rotating the activation ring 3 and the plunger rod 4.
  • the plunger rod 4 is free to move in the proximal direction by the force of the drive biasing member to expel the medicament.
  • stop notch 22 By said stop notch 22, an inadvertent activation of the medicament delivery device may by prevented since it provides an additional resistance which may not be overcome by accidental operation of the medicament delivery member cover 1. Moreover, the stop notch 22 during the activation state further urges the plunger rod 4 in the distal direction via the boss 41 overcoming the stop notch 22, thus further compressing the drive biasing member and providing a higher activation force when the device transitions from the activation state to the activated state.
  • Fig. 6A shows the dashed section of Fig. 1, i.e., the medicament delivery device in the assembled state, wherein the rear/distal housing 2 is transparently displayed.
  • the boss 41 is received in the cut-out 32, rests on and abuts the stop rib 21 and the optionally provided stop notch 22 and is thus prevented from moving in the proximal and radial direction.
  • Fig. 6B shows the device in the activated state. Again, the rear housing 2 is transparently displayed. Due to the interaction of the sloped surface 12 with the sloped protrusion 31 and in turn the interaction of the recess 32 with the boss 41, both the activation ring 3 and the plunger rod 4 have been rotated such that the boss 41 has passed the circumferential end of the stop rib 21 and the stop notch 22, respectively. As indicated by the arrow, the plunger rod 4 is now free to be moved in the proximal direction by the force of the drive biasing member to expel a medicament.
  • a stop notch (not shown) may be provided on the distal disk shaped end of the rear housing 2.
  • the activation ring 3 may comprise a corresponding protrusion (not shown).
  • a simple and safe plunger rod release mechanism may be provided.
  • the structure having a rotatable activation ring and a rotatable plunger rod require a slimmer distal end of the plunger rod and thus facilitate manufacturing and assembly.
  • the stop notch provides a further safety mechanism preventing inadvertent activation of the device.
  • the drive biasing member force on the plunger rod may be increased and the medicament delivery may thus be improved.
  • the delivery devices described herein can be used for the treatment and/or prophylaxis of one or more of many different types of disorders.
  • Exemplary disorders include, but are not limited to: rheumatoid arthritis, inflammatory bowel diseases (e.g. Crohn’s disease and ulcerative colitis), hypercholesterolaemia and/or dyslipidemia, cardiovascular disease, diabetes (e.g.
  • psoriasis psoriatic arthritis
  • spondyloarthritis hidradenitis suppurativa
  • Sjogren's syndrome migraine, cluster headache, multiple sclerosis, neuromyelitis optica spectrum disorder, anaemia, thalassemia, paroxysmal nocturnal hemoglobinuria, hemolytic anaemia, hereditary angioedema, systemic lupus erythematosus, lupus nephritis, myasthenia gravis, Behget's disease, hemophagocytic lymphohistiocytosis, atopic dermatitis, retinal diseases (e.g., age-related macular degeneration, diabetic macular edema), uveitis, infectious diseases, bone diseases (e.g., osteoporosis, osteopenia), asthma, chronic obstructive pulmonary disease, thyroid eye disease, nasal polyps, transplant, acute hypoglyca
  • Exemplary types of drugs that could be included in the delivery devices described herein include, but are not limited to, small molecules, hormones, cytokines, blood products, enzymes, vaccines, anticoagulants, immunosuppressants, antibodies, antibody-drug conjugates, neutralizing antibodies, reversal agents, radioligand therapies, radioisotopes and/or nuclear medicines, diagnostic agents, bispecific antibodies, proteins, fusion proteins, peptibodies, polypeptides, pegylated proteins, protein fragments, nucleotides, protein analogues, protein variants, protein precursors, protein derivatives, chimeric antigen receptor T cell therapies, cell or gene therapies, oncolytic viruses, or immunotherapies.
  • Exemplary drugs that could be included in the delivery devices described herein include, but are not limited to, immuno-oncology or bio-oncology medications such as immune checkpoints, cytokines, chemokines, clusters of differentiation, interleukins, integrins, growth factors, coagulation factors, enzymes, enzyme inhibitors, retinoids, steroids, signaling proteins, pro- apoptotic proteins, anti-apoptotic proteins, T-cell receptors, B-cell receptors, or costimulatory proteins.
  • immuno-oncology or bio-oncology medications such as immune checkpoints, cytokines, chemokines, clusters of differentiation, interleukins, integrins, growth factors, coagulation factors, enzymes, enzyme inhibitors, retinoids, steroids, signaling proteins, pro- apoptotic proteins, anti-apoptotic proteins, T-cell receptors, B-cell receptors, or costimulatory proteins.
  • Exemplary drugs that could be included in the delivery devices described herein include, but are not limited to, those exhibiting a proposed mechanism of action, such as human epidermal growth factor receptor 2 (HER-2) receptor modulators, interleukin (IL) modulators, interferon (IFN) modulators, complement modulators, glucagon-like peptide-i (GLP-i) modulators, glucose-dependent insulinotropic polypeptide (GIP) modulators, cluster of differentiation 38 (CD38) modulators, cluster of differentiation 22 (CD22) modulators, Ci esterase modulators, bradykinin modulators, C-C chemokine receptor type 4 (CCR4) modulators, vascular endothelial growth factor (VEGF) modulators, B-cell activating factor (BAFF), P-selectin modulators, neonatal Fc receptor (FcRn) modulators, calcitonin gene-related peptide (CGRP) modulators, epidermal growth factor receptor (EGFR) modulators, cluster of differentiation 79B (CD79B
  • Exemplary drugs that could be included in the delivery devices described herein include, but are not limited to: etanercept, abatacept, adalimumab, evolocumab, exenatide, secukinumab, erenumab, galcanezumab, fremanezumab-vfrm, alirocumab, methotrexate (amethopterin), tocilizumab, interferon beta-ia, interferon beta-ib, peginterferon beta-ia, sumatriptan, darbepoetin alfa, belimumab, sarilumab, semaglutide, dupilumab, reslizumab, omalizumab, glucagon, epinephrine, naloxone, insulin, amylin, vedolizumab, eculizumab, ravulizumab, crizanlizuma
  • Exemplary drugs that could be included in the delivery devices described herein may also include, but are not limited to, oncology treatments such as ipilimumab, nivolumab, pembrolizumab, atezolizumab, durvalumab, avelumab, cemiplimab, rituximab, trastuzumab, ado-trastuzumab emtansine, fam-trastuzumab deruxtecan-nxki, pertuzumab, transtuzumab-pertuzumab, alemtuzumab, belantamab mafodotin-blmf, bevacizumab, blinatumomab, brentuximab vedotin, cetuximab, daratumumab, elotuzumab, gemtuzumab ozogamicin, 90-Yttrium-ibritumo
  • Exemplary drugs that could be included in the delivery devices described herein include “generic” or biosimilar equivalents of any of the foregoing, and the foregoing molecular names should not be construed as limiting to the “innovator” or “branded” version of each, as in the non-limiting example of innovator medicament adalimumab and biosimilars such as adalimumab- afzb, adalimumab-atto, adalimumab-adbm, and adalimumab-adaz.
  • Exemplary drugs that could be included in the delivery devices described herein also include, but are not limited to, those used for adjuvant or neoadjuvant chemotherapy, such as an alkylating agent, plant alkaloid, antitumor antibiotic, antimetabolite, or topoisomerase inhibitor, enzyme, retinoid, or corticosteroid.
  • adjuvant or neoadjuvant chemotherapy such as an alkylating agent, plant alkaloid, antitumor antibiotic, antimetabolite, or topoisomerase inhibitor, enzyme, retinoid, or corticosteroid.
  • Exemplary chemotherapy drugs include, by way of example but not limitation, 5-fluorouracil, cisplatin, carboplatin, oxaliplatin, doxorubicin, daunorubicin, idarubicin, epirubicin, paclitaxel, docetaxel, cyclophosphamide, ifosfamide, azacitidine, decitabine, bendamustine, bleomycin, bortezomib, busulfan, cabazitaxel, carmustine, cladribine, cytarabine, dacarbazine, etoposide, fludarabine, gemcitabine, irinotecan, leucovorin, melphalan, methotrexate, pemetrexed, mitomycin, mitoxantrone, temsirolimus, topotecan, valrubicin, vincristine, vinblastine, or vinorelbine.
  • Exemplary drugs that could be included in the delivery devices described herein also include, but are not limited to, analgesics (e.g., acetaminophen), antipyretics, corticosteroids (e.g. hydrocortisone, dexamethasone, or methylprednisolone), antihistamines (e.g., diphenhydramine or famotidine), antiemetics (e.g., ondansetron), antibiotics, antiseptics, anticoagulants, fibrinolytics (e.g., recombinant tissue plasminogen activator [r-TPA]), antithrombolytics, or diluents such as sterile water for injection (SWFI), 0.9% Normal Saline, 0.45% normal saline, 5% dextrose in water, 5% dextrose in 0.45% normal saline, Lactated Ringer’s solution, Heparin Lock Flush solution, 100 U/mL Heparin Lock Flush Solution, or
  • compositions including, but not limited to, any drug described herein are also contemplated for use in the delivery devices described herein, for example pharmaceutical formulations comprising a drug as listed herein (or a pharmaceutically acceptable salt of the drug) and a pharmaceutically acceptable carrier.
  • Such formulations may include one or more other active ingredients (e.g., as a combination of one or more active drugs), or may be the only active ingredient present, and may also include separately administered or co-formulated dispersion enhancers (e.g. an animal-derived, human-derived, or recombinant hyaluronidase enzyme), concentration modifiers or enhancers, stabilizers, buffers, or other excipients.
  • Exemplary drugs that could be included in the delivery devices described herein include, but are not limited to, a multi-medication treatment regimen such as AC, Dose-Dense AC, TCH, GT, EC, TAC, TC, TCHP, CMF, FOLFOX, mFOLFOX6, mFOLFOXy, FOLFCIS, CapeOx, FLOT, DCF, FOLFIRI, FOLFIRINOX, FOLFOXIRI, IROX, CHOP, R-CHOP, RCHOP-21, Mini- CHOP, Maxi-CHOP, VR-CAP, Dose-Dense CHOP, EPOCH, Dose-Adjusted EPOCH, R-EPOCH, CODOX-M, IVAC, HyperCVAD, R-HyperCVAD, SC- EPOCH-RR, DHAP, ESHAP, GDP, ICE, MINE, CEPP, CDOP, GemOx, CEOP, CEPP, CHOEP, CHP, GCVP, DHAX

Landscapes

  • Health & Medical Sciences (AREA)
  • Vascular Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

L'invention concerne un dispositif d'administration de médicament, comprenant : un boîtier arrière (2) situé au niveau d'une extrémité distale du dispositif d'administration de médicament, l'extrémité distale étant orientée dans le sens opposé à un site d'administration de médicament pendant l'utilisation du dispositif d'administration de médicament, un couvercle d'élément d'administration de médicament (1), une bague d'activation rotative (3) et une tige de piston rotative (4), le couvercle d'élément d'administration de médicament (1) comprenant au moins une surface inclinée (12) conçue pour interagir avec au moins une saillie inclinée correspondante (31) disposée sur la bague d'activation rotative (3), la bague d'activation (3) comprenant au moins un évidement (32) conçu pour interagir avec au moins un bossage correspondant (41) disposé sur la tige de piston rotative (4), et le bossage (41) venant en butée contre une nervure d'arrêt (21) disposée au niveau du boîtier arrière (2).
EP23837222.1A 2023-01-04 2023-12-20 Dispositif d'administration de médicament Pending EP4646247A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP23150289 2023-01-04
PCT/EP2023/086895 WO2024146801A1 (fr) 2023-01-04 2023-12-20 Dispositif d'administration de médicament

Publications (1)

Publication Number Publication Date
EP4646247A1 true EP4646247A1 (fr) 2025-11-12

Family

ID=84820357

Family Applications (1)

Application Number Title Priority Date Filing Date
EP23837222.1A Pending EP4646247A1 (fr) 2023-01-04 2023-12-20 Dispositif d'administration de médicament

Country Status (2)

Country Link
EP (1) EP4646247A1 (fr)
WO (1) WO2024146801A1 (fr)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2538566B (en) * 2015-05-22 2020-09-30 Owen Mumford Ltd Injection device
TWI678221B (zh) * 2017-09-28 2019-12-01 瑞士商瑞健醫療股份有限公司 驅動單元
US12208245B2 (en) * 2019-09-30 2025-01-28 Amgen Inc. Drug delivery device
EP4192547A1 (fr) * 2020-08-07 2023-06-14 Sanofi Système d'entraînement pour dispositif d'administration de médicament

Also Published As

Publication number Publication date
WO2024146801A1 (fr) 2024-07-11

Similar Documents

Publication Publication Date Title
EP4651923A1 (fr) Dispositif d'administration de médicament et ensemble d'administration de médicament
WO2024188693A1 (fr) Dispositif d'administration de médicament
WO2024146801A1 (fr) Dispositif d'administration de médicament
WO2025113819A1 (fr) Dispositif d'administration de médicament
EP4646249A1 (fr) Dispositif d'administration de médicament
WO2024156427A1 (fr) Dispositif d'administration de médicament
WO2025237664A1 (fr) Dispositif d'administration de médicament ayant un mécanisme de libération de tige de piston
EP4646248A1 (fr) Dispositif d'administration de médicament
WO2024146819A1 (fr) Dispositif d'administration de médicament
EP4646252A1 (fr) Dispositif d'administration de médicaments
EP4655031A1 (fr) Dispositif d'administration de médicament
WO2025228678A1 (fr) Sous-ensemble pour un dispositif d'administration de médicament
WO2025051705A1 (fr) Ensemble d'entraînement pour dispositif d'administration de médicament
WO2026008320A1 (fr) Ensemble d'entraînement pour dispositif d'administration de médicament
EP4633702A1 (fr) Dispositif de sécurité à injection pour administrer un médicament
WO2025176498A1 (fr) Ensemble capuchon pour un dispositif d'administration de médicament
WO2024156432A1 (fr) Dispositif d'administration de médicament
WO2024251540A1 (fr) Sous-ensemble pour dispositif d'administration de médicament
WO2025180828A1 (fr) Capuchon pour dispositif d'administration de médicament
WO2026077907A1 (fr) Mécanisme d'actionnement
WO2025098848A1 (fr) Ensemble pour dispositif d'administration de médicament
WO2025113999A1 (fr) Dispositif d'administration de médicament
WO2025214783A1 (fr) Unité de surveillance pour un dispositif d'administration de médicament entraîné par un ressort de torsion
WO2025157561A1 (fr) Sous-ensemble pour dispositif de délivrance de médicament
WO2025153310A1 (fr) Auto-injecteur

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20250722

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)